Comparative Pharmacology
Head-to-head clinical analysis: AUVELITY versus QMIIZ ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUVELITY versus QMIIZ ODT.
AUVELITY vs QMIIZ ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AUVELITY (dextromethorphan HBr and bupropion HCl) is an NMDA receptor antagonist (via dextromethorphan) and a norepinephrine-dopamine reuptake inhibitor (via bupropion). Dextromethorphan also modulates sigma-1 receptor activity.
QMIIZ ODT is a centrally acting alpha-2 adrenergic agonist that modulates norepinephrine release by binding to presynaptic alpha-2 adrenergic receptors, reducing sympathetic outflow from the brainstem and lowering blood pressure.
45 mg orally once daily, given as dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg combination tablet.
20 mg sublingually once daily in the morning.
None Documented
None Documented
Dextromethorphan: 13.5 hours (terminal half-life; prolonged due to CYP2D6 inhibition by bupropion, allowing sustained NMDA antagonism; bupropion: 13.7 hours)
Terminal elimination half-life is 10–12 hours in healthy adults, allowing once-daily dosing.
Renal 81% (dextromethorphan and metabolites: 78% as unchanged drug and 3% as dextrorphan conjugates), fecal 9% (dextromethorphan and metabolites), biliary <1%
Primarily renal (90% as unchanged drug in urine), with minor fecal excretion (<5% as metabolites).
Category C
Category C
Antidepressant
Antidepressant